Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C


Journal

Monoclonal antibodies in immunodiagnosis and immunotherapy
ISSN: 2167-9436
Titre abrégé: Monoclon Antib Immunodiagn Immunother
Pays: United States
ID NLM: 101590955

Informations de publication

Date de publication:
Oct 2021
Historique:
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 14 1 2022
Statut: ppublish

Résumé

CD44 is a type I transmembrane protein expressed in various kinds of normal cancer cells, including pancreatic, breast, and oral cancers. CD44 is associated with cancer progression, metastases, and treatment resistance. CD44 consists of 20 exons, and various isoforms exist due to alternative splicing of the central 10 exons. Some splicing variants show cancer-specific expression patterns and are related to prognosis of patients with cancer. Therefore, CD44 targeting therapy has been attracting attention. In a previous study, we established an anti-CD44 monoclonal antibody, C

Identifiants

pubmed: 34678095
doi: 10.1089/mab.2021.0028
doi:

Substances chimiques

Antibodies, Monoclonal 0
Hyaluronan Receptors 0
Alanine OF5P57N2ZX

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-226

Auteurs

Junko Takei (J)

Department of Antibody Drug Development, and Tohoku University Graduate School of Medicine, Sendai, Japan.

Teizo Asano (T)

Department of Antibody Drug Development, and Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroyuki Suzuki (H)

Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Mika K Kaneko (MK)

Department of Antibody Drug Development, and Tohoku University Graduate School of Medicine, Sendai, Japan.

Yukinari Kato (Y)

Department of Antibody Drug Development, and Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH